Too Late to Work:
The Cancer Vaccine Timing Problem
Most personalised cancer vaccines today are made too late – after surgery – when the cancer has already grown. We’re building a tool to design personalised vaccines much earlier, aiming to stop cancer before it becomes dangerous.
average mutation targets considered per patient
659
too many to test, most are irrelevant
filtered out due to poor immune visibility
98%
few have a chance of being useful
actually selected for vaccine
11
most don’t make the cut
trigger an immune response in patients
38%
many vaccines never work as hoped
In our analysis of 478 cancer vaccine trials, most failed for the same reason: they were designed too late and targeted the wrong mutations. Current pipelines struggle to find the right targets in time. We built Serova to change that – by selecting the right mutations, much earlier.
Our pipeline.
We identify mutations that cause cancer and predict which are most likely to alert the immune system.
Serova ranks these mutations and turns them into personalised vaccine blueprints that help the body fight cancer early.
The Team
Matthew Dean
ceo
